Journal of Pharmaceutical and Biomedical Sciences

Login
Select Language
Subscription Login to verify subscription
Give a gift subscription
Article Tools
Print this article
Indexing metadata
How to cite item
Finding References
Review policy
Email this article (Login required)
Email the author(Login required)
Post a Comment (Login required)

In vitro Anticancer Activity of Doxorubicin-Loading Pectin Nanoparticles

Gong Tian, Zhou Guifang, Ye Qiumian, Kuang Jianyuan, Ou Jinlai, Xu Zhenxia, Zhao Wen, Li Sha

Abstract


By using pectin (PEC) as carrier material and doxorubicin (DOX) as a model drug, the blank PEC nanoparticles (PEC-NPs) and the DOX-loading PEC nanoparticles (DOX-PEC-NPs) were prepared by microemulsification method and drug adsorption. The aim of this study is to investigate the anticancer activity of DOX-PEC-NPs in vitro to understand the advantages of PEC-NPs as an anticancer drug delivery system. The particle size, polydispersity index (PDI) and zeta potential of PEC-NPs were (276.80 ± 2.80) nm, (0.140 ± 0.014) and (?19.83 ± 0.21) mV, while those of DOX-PEC-NPs were (283.73 ± 3.26) nm, (0.157 ± 0.034) and (?18.00 ± 0.44) mV. The entrapment efficiency (EE%) and drug-loading rate (LR%) of DOX-PEC-NPs were (92.10 ± 0.60)% and (18.72 ± 0.10)%, respectively. Using an MTT assay, the DOX-PEC-NPs were proved to greatly inhibit the viability of MDAMB- 231 cells, A549 cells and NCI-H1299 cells, and the anticancer activity was higher than that of the DOX solution in these cells. The PEC-NPs had no cytotoxicity against the three tested cells. An inverted fluorescence microscope and flow cytometry were used to observe the intracellular uptake of DOX. The DOX-PEC-NPs resulted in faster and more DOX uptake than DOX solution in the tested cells. The results indicated that the PEC-NPs may be a potential anticancer drug delivery system which could reduce the dose and increase the activity of anticancer drugs.

Keywords


doxorubicin, pectin, nanoparticle, anticancer activity

Full Text:

References


Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331–41.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

Zhang N, Klegerman ME, Deng H, Shi Y, Golunski E, An Z. Trastuzumab–doxorubicin conjugate provides enhanced anticancer potency and reduced cardiotoxicity. J Cancer Ther. 2013;04:308–22.

Lei H, Wang X, Wu C. Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations. J Mol Graph Model. 2012;38:279–89. 6. Evans AR, Miriyala S, St Clair DK, Butterfield DA, Robinson RA. Global effects of adriamycin treatment on mouse splenic protein levels. J Proteome Res. 2012;11:1054–64.

Farrell D, Alper J, Ptak K, Panaro NJ, Grodzinski P, Barker AD. Recent advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano. 2010;4:589–94.

Raj R, Das S. Prospects of bacteriotherapy with nanotechnology in nanoparticledrug conjugation approach for cancer therapy. Curr Med Chem. 2016;23:1477–94.

Spyratou E, Makropoulou M, Mourelatou EA, Demetzos C. Biophotonic techniques for manipulation and characterization of drug delivery nanosystems in cancer therapy. Cancer Lett. 2012;327:111–22.

Sengupta S, Sasisekharan R. Exploiting nanotechnology to target cancer. Br J Cancer. 2007;96:1315–9.

Zhuang Y, Deng H, Su Y, He L, Wang R, Tong G, et al. Aptamerfunctionalized and backbone redox-responsive hyperbranched polymer for targeted drug delivery in cancer therapy. Biomacromolecules.

[Epub ahead of print].

d’Ayala GG, Malinconico M, Laurienzo P. Marine derived polysaccharides for biomedical applications: chemical modification approaches. Molecules. 2008;13:2069–106.

Yuan Q, Venkatasubramanian R, Hein S, Misra RD. A stimulus- responsive magnetic nanoparticle drug carrier: magnetite encapsulated by chitosan-grafted-copolymer. Acta biomater. 2008;4:1024–37.

Liu L, Fishman ML, Hicks KB. Pectin in controlled drug delivery: a review. Cellulose. 2006;14:15–24.

Katav T, Liu L, Traitel T, Goldbart R, Wolfson M, Kost J. Modified pectin-based carrier for gene delivery: cellular barriers in gene delivery course. J Control Release. 2008;130:183–91.

Wen S, Ou J, Luo R, Liang W, OuYang P, Zeng F, et al. Preparation and release behavior of pectin nanoparticles loading doxorubicin. J Pharm Biomed Sci. 2015;5:385–93.

Ou J, Hong B, Ye X, Feng C, Gong T, Li S. Preparation and anti-tumor activity of doxorubicin-loading pectin nanoparticles in vitro. J Jinan Univ. 2014;35:330–6.

Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466–8.

Yao F, Duan J, Wang Y, Zhang Y, Guo Y, Guo H, et al. Nanopore single-molecule analysis of DNA-doxorubicin interactions. Anal Chem. 2015;87:338–42.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.